NAVULTRA registry compares Navitor vs. SAPIEN 3 Ultra in TAVR, revealing key tradeoffs in pacemaker use, PVL, and HF outcomes
Interventional Cardiology
Advertisement
The FDA approved the use of Edwards Lifesciences' SAPIEN 3 TAVR platform for patients with severe aortic stenosis.
Dr. Amit Goyal of the CardioNerds analyzed the BHF PROTECT-TAVI trial.
The REPAIR study offers the most comprehensive real-world assessment of outcomes after mitral TEER.
The ROLLER COASTR-EPIC22 trial is the first randomized head-to-head comparison of three plaque modification techniques.
Patients between the ages of 50 and 70 years with a mechanical heart valve have better long-term survival.
Coronary Sinus Reducer Demonstrates Long-Term Efficacy in Refractory Angina: Insights from REDUCER-I
The observational REDUCER-I study aims to evaluate the real-world safety and effectiveness of the coronary sinus reducer.Expert Interviews
Cardio Care Today delivers the latest medical industry news, giving health care professionals the curated content most relevant to their fields and practices.
Get the latest medical updates and insights straight to your inbox.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.